In case you’ve missed the previous episodes, find them all here!
Don't miss out and complete this form
The Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR) represent a challenge for all of us. But where there is a challenge, there is always an opportunity!
This is our chance to meet the challenge together and work in partnership to ensure a smooth transition to IVDR compliance.
With the positive changes that the MDR and IVDR will bring to the European regulatory framework, we look forward to having our products and unique technologies continue to serve you and your patients.
The EU IVDR affects all IVD medical devices and will bring about several changes. Manufacturers are reviewing their product portfolio, and certain devices may be discontinued.
Health Institutions (HIs) should be aware which of their products will be affected and prepare ahead to ensure continuity after the IVDR date of application.
LDTs (Lab Developed Tests) are in scope of the IVDR as well, which means that the LDT needs to meet certain requirements and the health institution can only use the LDT if certain conditions are met.
Planning and preparedness are key!
The EU In Vitro Diagnostic Medical Device Regulation 2017/746 (IVDR) took effect on 26 May 2017, and a transitional period of 5 years is in force till 26 May 2022.
The IVDR replaces the EU's current Directive on In Vitro Diagnostic medical Device (IVDD) (98/79/EC) to ostensibly ensure a higher level of health and safety for making available and putting into service devices in the EU market and setting new rules for applying a CE mark to IVDs. Being a regulation, it does not need to be transposed into the National Law and hence ensures uniform interpretation throughout the Union.
LDTs are now governed by the IVDR.
Rules for the use and manufacturing of LDTs have now been established under the IVDR to ensure the highest level of protection, which is one of the main objectives of the IVDR.
No requirements are described for LDTs in the existing IVD Directive (98/79/EC).
The LDT shall be manufactured and used within framework of a Quality Management System
The HI shall be accredited according to EN ISO 15189 (or alternate national provisions)
The LDT must comply with General Safety and Performance Requirements (GSPR – Annex I of the IVDR)
The HI will review experience gained from clinical use and takes the corrective actions, where necessary
The HI will compile documentation on device manufacturing, design and performance
The HI will make a declaration of conformity publicly available
Health Institutions should prepare documentation that describes:
The documentation should be of sufficient detail to demonstrate that all applicable GSPR as outlined in Annex 1 are met.
The IVDR prescribes the above requirement for class D devices. However, the Regulations allows Member States to apply this provision also to class A, B or C devices.
NB ( Notified Body) = Notified body is a third-party certification body that conducts conformity assessments for those devices that are not self-certified. If compliance is demonstrated, the CE-certificate will be issued by the notified body and the manufacturer can draw up the DoC
DoC (Declaration of Conformity) = The DoC serves as a confirmation that all applicable CE-marking legislations are met for the listed devices.
For manufacturers, the IVDR foresees a conformity assessment route for each risk class as a prerequisite for the Declaration of Conformity, and where applicable the CE-certificate.
There are additional requirements for Classes C and D
Additional considerations for specific device types
New requirements for the DoC document compared to IVDD:
* SRN is a unique number that will be assigned to the Economic Operator [Manufacturer, Authorized Representative, Importer] after registering in EUDAMED.